CuraTeQ Biologics receives approval for oncology biosimilar Bevqolva from UK's MHRA

CuraTeQ Biologics s.r.o., a step-down subsidiary of Aurobindo Pharma Limited, is pleased to announce that it has obtained marketing authorisation from UK's Medicines and Healthcare products Regulatory Agency (MHRA) for Bevqolva, its bevacizumab biosimilar version.

Bevqolva 25 mg/mL concentrate for infusion will be available in 4 mL (100 mg) and 16 mL (400 mg) single-use vials for infusion into veins.

Bevacizumab is used in the treatment of multiple cancers including metastatic colorectal cancer, recurrent or metastatic non-squamous non-small cell lung cancer, advanced and/or metastatic renal cell carcinoma, cervical cancer and epithelial ovarian, fallopian tube and primary peritoneal cancer.

Shares of Aurobindo Pharma Limited was last trading in BSE at Rs. 1240.70 as compared to the previous close of Rs. 1255.40. The total number of shares traded during the day was 31561 in over 3015 trades.

The stock hit an intraday high of Rs. 1274.70 and intraday low of 1235.15. The net turnover during the day was Rs. 39831332.00.

Source : Equity Bulls

Keywords

AurobindoPharma INE406A01037 CuraTeQBiologicssro UK MHRa Bevqolva Bevacizumab Biosimilar